AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$52.03 USD
+0.17 (0.33%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMN) Outperforming Other Medical Stocks This Year?
AMN Healthcare (AMN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 11.56% and 3.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.
AMN Healthcare Services (AMN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.
CONMED's (CNMD) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
CONMED (CNMD) witnesses revenue uptick in both of its segments during Q2 despite continued pandemic-led business disruptions.
NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.
Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Baxter's (BAX) second-quarter results reflect robust performance across all its business units.
West Pharmaceutical (WST) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strong segmental performance.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.
Align Technology (ALGN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Invisalign Clear Aligners and iTero scanners sales volumes during the fiscal second quarter drove Align Technology's (ALGN) top line.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $98.47, moving -0.64% from the previous trading session.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.
Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.
Ecolab (ECL) Q2 Earnings & Revenues Beat Mark, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performances across majority of its segments drive its Q2 sales despite pandemic-led business challenges.
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
by Zacks Equity Research
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
by Zacks Equity Research
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.